TOP TIERMARKET NEWSWIRE

News & sentiment

OPUS GENETICS INC (IRD) — News & AI sentiment

OPUS GENETICS INC (IRD) news roundup. 17 stories in the past week, 28 over 30 days. Average 30-day sentiment is 59.2/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 5 sales totalling $214K — net selling of $214K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

17

avg sentiment 62/100

30d stories

28

avg sentiment 59.2/100

Insider net (90d)

$214K

0 buys · 5 sells

Congress (90d)

0

0 buys · 0 sells

IRD news in the last 24 hours, 7 days, 30 days and 90 days

How much IRD coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	IRD stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	17	62/100	IRD headlines →
Last 30 days	28	59.2/100	IRD headlines →
Last 90 days	71	61/100	IRD headlines →

Latest stories on IRD

Opus Genetics, Inc. (IRD) files 8-K

SEC 8-K50 · neutralgeneral

2d ago

Opus Genetics: A Resounding Study Success Merits A Higher Valuation

Seeking Alpha73 · bullishproduct/pr

3d ago

Halper Sadeh LLC is Investigating Whether CSR, IRDM, CBAN, LAB are Obtaining Fair Deals for their Shareholders

GlobeNewswire34 · bearishgeneral

3d ago

Opus Genetics price target raised to $14 from $11 at Leerink

The Fly61 · neutralanalyst

4d ago

Opus Genetics price target raised to $20 from $10 at Oppenheimer

The Fly63 · neutralanalyst

4d ago

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow

Seeking Alpha50 · neutralgeneral

4d ago

Opus Genetics Shares Reach 52-Week High on Clinical Trial, FDA Progress

Morningstar73 · bullishproduct/pr

4d ago

Opus Genetics Shares Reach 52-Week High on Clinical Trial, FDA Progress

MarketWatch76 · bullishproduct/pr

4d ago

Opus Genetics price target raised to $16 from $13 at Chardan

The Fly61 · neutralanalyst

4d ago

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

Stocktwits News63 · neutralproduct/pr

4d ago

Wedbush raises Opus Genetics stock price target on FDA alignment

Investing.com Analyst Ratings61 · neutralanalyst

4d ago

Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data

TipRanks73 · bullishproduct/pr

4d ago

Opus Genetics announces results from low-dose Cohort 1 of BIRD-1 trial

The Fly59 · neutralproduct/pr

4d ago

Opus Genetics, Inc. (IRD) files 8-K

SEC 8-K50 · neutralgeneral

4d ago

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Business Insider73 · bullishproduct/pr

4d ago

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

GlobeNewswire73 · bullishproduct/pr

4d ago

Opus Genetics stock rating reaffirmed at Buy by H.C. Wainwright

Investing.com Analyst Ratings61 · neutralanalyst

5d ago

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

GlobeNewswire63 · neutralproduct/pr

Sep 2

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

Business Insider63 · neutralproduct/pr

Sep 2

Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data

Yahoo Finance63 · neutralproduct/pr

Sep 1

Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data

InvestorsHub63 · neutralproduct/pr

Sep 1

Why is Opus Genetics stock rallying today?

Investing.com Markets50 · neutralgeneral

Sep 1

Citizens reiterates Opus Genetics stock rating on Viatris partnership potential

Investing.com Analyst Ratings56 · neutralanalyst

Aug 28

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

GlobeNewswire34 · bearishgeneral

Aug 24

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire50 · neutralgeneral

Aug 19

Open IRD in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →